共同药业(300966)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

300966 共同药业

已收盘 03-18 15:00:00

{"stockData":{"symbol":"300966","market":"SZ","secType":"STK","nameCN":"共同药业","latestPrice":21.3,"timestamp":1773817419000,"preClose":20.86,"halted":0,"volume":1353000,"delay":0,"changeRate":0.0211,"floatShares":76368300,"shares":114999999,"eps":-0.3979,"marketStatus":"已收盘","change":0.44,"latestTime":"03-18 15:00:00","open":21.03,"high":21.31,"low":20.83,"amount":28522200,"amplitude":0.023,"askPrice":21.3,"askSize":130,"bidPrice":21.29,"bidSize":54,"shortable":0,"etf":0,"ttmEps":-0.3979,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1773883800000},"marketStatusCode":5,"adr":0,"adjPreClose":20.86,"symbolType":"stock","openAndCloseTimeList":[[1773797400000,1773804600000],[1773810000000,1773817200000]],"highLimit":22.95,"lowLimit":18.77,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":115281113,"isCdr":false,"pbRate":3.1,"roa":"--","roe":"--","epsLYR":-0.24,"committee":-0.391791,"marketValue":2455000000,"turnoverRate":0.0177,"status":0,"floatMarketCap":1627000000},"requestUrl":"/m/hq/s/300966","defaultTab":"news","newsList":[{"id":"2620137257","title":"共同药业（300966）披露2026年度日常关联交易预计公告，3月18日股价上涨2.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2620137257","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620137257?lang=zh_cn&edition=full","pubTime":"2026-03-18 22:58","pubTimestamp":1773845893,"startTime":"0","endTime":"0","summary":"截至2026年3月18日收盘，共同药业报收于21.3元，较前一交易日上涨2.11%，最新总市值为24.55亿元。公司于近日披露《关于公司2026年度日常关联交易预计的公告》。公告显示，湖北共同药业股份有限公司预计2026年度与关联方山东同新药业有限公司发生日常关联交易总额不超过4,500万元，其中向关联人采购原材料不超过2,000万元，销售甾体药物起始物料不超过2,500万元，定价遵循市场价格原则。2025年度实际发生关联交易金额为1,824.88万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031800041136.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300966","BK0239"],"gpt_icon":0},{"id":"2606626518","title":"股市必读：共同药业（300966）1月23日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2606626518","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606626518?lang=zh_cn&edition=full","pubTime":"2026-01-26 03:22","pubTimestamp":1769368932,"startTime":"0","endTime":"0","summary":"截至2026年1月23日收盘，共同药业报收于21.58元，上涨1.17%，换手率2.13%，成交量1.62万手，成交额3499.06万元。交易信息汇总资金流向1月23日主力资金净流出206.02万元；游资资金净流出237.5万元；散户资金净流入443.52万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012600001493.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300966","BK0239"],"gpt_icon":0},{"id":"2605421072","title":"共同药业：孕激素类产品可用于妇科及计生用药","url":"https://stock-news.laohu8.com/highlight/detail?id=2605421072","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605421072?lang=zh_cn&edition=full","pubTime":"2026-01-23 15:12","pubTimestamp":1769152326,"startTime":"0","endTime":"0","summary":"投资者提问：贵公司在辅助生殖领域的药物是否满足海外市场标准，目前出口销售共同药业回复：尊敬的投资者，您好，公司主要从事甾体药物原料的研发、生产及销售，公司募投项目及甾体原料药生产建设项目中的孕激素类产品向下游延伸可用于生产妇科及计生用药等；公司产品根据销售区域主要分为境内销售与境外销售，具体销售数据详见定期报告中第三部分“管理层讨论与分析”之“主营业务分析”的内容，感谢您对公司的关注!","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012300019357.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300966","BK0239"],"gpt_icon":0},{"id":"2604974170","title":"股市必读：共同药业（300966）预计2025年全年扣非后净利润亏损5900万元至7600万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2604974170","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604974170?lang=zh_cn&edition=full","pubTime":"2026-01-19 03:26","pubTimestamp":1768764370,"startTime":"0","endTime":"0","summary":"截至2026年1月16日收盘，共同药业报收于20.96元，下跌0.66%，换手率1.79%，成交量1.36万手，成交额2858.35万元。当日关注点来自交易信息汇总：1月16日主力资金净流出425.53万元，散户资金净流入517.69万元。业绩披露要点业绩预告共同药业发布业绩预告，预计2025年全年扣非后净利润亏损5900万元至7600万元；预计2025年全年归属净利润亏损5800万元至7500万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011900001255.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300966"],"gpt_icon":0},{"id":"2603093969","title":"共同药业2025年业绩预告：预计亏损5800万至7500万元，同比由盈转亏","url":"https://stock-news.laohu8.com/highlight/detail?id=2603093969","media":"中金财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603093969?lang=zh_cn&edition=full","pubTime":"2026-01-16 17:22","pubTimestamp":1768555336,"startTime":"0","endTime":"0","summary":"中访网数据 湖北共同药业股份有限公司于2026年1月16日发布2025年度业绩预告。预告显示，公司预计2025年度归属于上市公司股东的净利润为亏损5,800万元至7,500万元，较上年同期盈利2,759.11万元相比，业绩大幅下滑，预计同比下降110.21%至171.83%；扣除非经常性损益后的净利润预计为亏损5,900万元至7,600万元。本次业绩预告数据未经会计师事务所审计，具体财务数据将在公司2025年年度报告中详细披露。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20260116/31948865.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0239","300966"],"gpt_icon":0},{"id":"2601838375","title":"共同药业（300966）披露2025年第四季度可转换公司债券转股情况，1月5日股价上涨3.3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601838375","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601838375?lang=zh_cn&edition=full","pubTime":"2026-01-05 23:15","pubTimestamp":1767626118,"startTime":"0","endTime":"0","summary":"截至2026年1月5日收盘，共同药业报收于20.34元，较前一交易日上涨3.3%，最新总市值为23.45亿元。该股当日开盘19.8元，最高20.35元，最低19.63元，成交额达3719.13万元，换手率为2.41%。公司于近日发布关于2025年第四季度可转换公司债券转股情况的公告。公告显示，2025年第四季度，共有10张“共同转债”完成转股，合计转成36股公司股票。截至2025年12月31日，公司剩余可转债为3,798,878张，剩余票面总额379,887,800元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010500041053.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300966","BK0239"],"gpt_icon":0},{"id":"2585651384","title":"共同药业可转债将于11月28日付息","url":"https://stock-news.laohu8.com/highlight/detail?id=2585651384","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585651384?lang=zh_cn&edition=full","pubTime":"2025-11-24 18:35","pubTimestamp":1763980502,"startTime":"0","endTime":"0","summary":"中访网数据 湖北共同药业股份有限公司发布公告，其发行的“共同转债”将于2025年11月28日支付第三年利息。本次付息的债权登记日为2025年11月27日，凡在该日收市后登记在册的债券持有人均享有本次利息。本期债券计息期间为2024年11月28日至2025年11月27日，票面利率为1.1%，即每10张面值1000元的债券派发利息11元(含税)。本次付息完成后，“共同转债”下一计息年度的票面利率将为1.80%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20251124/31819855.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["300966","BK0239"],"gpt_icon":0},{"id":"2579916671","title":"共同药业（300966）2025年三季报简析：增收不增利","url":"https://stock-news.laohu8.com/highlight/detail?id=2579916671","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579916671?lang=zh_cn&edition=full","pubTime":"2025-10-29 06:43","pubTimestamp":1761691401,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期共同药业发布2025年三季报。根据财报显示，共同药业增收不增利。其中，毛利率18.49%，同比增29.98%，净利率-8.23%，同比减81.84%，销售费用、管理费用、财务费用总计8193.99万元，三费占营收比18.01%，同比增6.96%，每股净资产6.72元，同比减7.94%，每股经营性现金流-0.05元，同比减106.61%，每股收益-0.28元，同比减133.33%证券之星价投圈财报分析工具显示：业务评价：去年的净利率为-5.9%，算上全部成本后，公司产品或服务的附加值不高。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102900010856.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300966"],"gpt_icon":0},{"id":"2578795182","title":"太平洋：给予共同药业增持评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2578795182","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578795182?lang=zh_cn&edition=full","pubTime":"2025-10-28 20:15","pubTimestamp":1761653739,"startTime":"0","endTime":"0","summary":"太平洋证券股份有限公司周豫,乔露阳近期对共同药业进行研究并发布了研究报告《Q3营收快速增长，在建工程陆续转固》，给予共同药业增持评级。截至2025年9月底，公司固定资产合计为16.17亿元，相较6月底增加了4.80亿元，华海共同部分在建工程转固。最新盈利预测明细如下：该股最近90天内共有1家机构给出评级，增持评级1家。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102800037270.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["601099","300966"],"gpt_icon":0},{"id":"2578064108","title":"共同药业(300966.SZ)发布前三季度业绩，归母净亏损3243.49万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2578064108","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578064108?lang=zh_cn&edition=full","pubTime":"2025-10-27 21:15","pubTimestamp":1761570934,"startTime":"0","endTime":"0","summary":"智通财经APP讯，共同药业(300966.SZ)发布2025年三季度报告，该公司前三季度营业收入为4.55亿元，同比增长24.54%。归属于上市公司股东的净亏损为3243.49万元。归属于上市公司股东的扣除非经常性损益的净亏损为3221.48万元。基本每股亏损为0.28元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1360698.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"共同药业(300966.SZ)发布前三季度业绩，归母净亏损3243.49万元","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","300966"],"gpt_icon":0},{"id":"2578610496","title":"图解共同药业三季报：第三季度单季净利润同比下降135.33%","url":"https://stock-news.laohu8.com/highlight/detail?id=2578610496","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578610496?lang=zh_cn&edition=full","pubTime":"2025-10-27 19:04","pubTimestamp":1761563080,"startTime":"0","endTime":"0","summary":"证券之星消息，共同药业2025年三季报显示，公司主营收入4.55亿元，同比上升24.54%；归母净利润-3243.49万元，同比下降129.02%；扣非净利润-3221.48万元，同比下降118.1%；其中2025年第三季度，公司单季度主营收入1.53亿元，同比上升16.04%；单季度归母净利润-2128.24万元，同比下降135.33%；单季度扣非净利润-2199.57万元，同比下降123.45%；负债率66.47%，投资收益-35.88万元，财务费用3417.69万元，毛利率18.49%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102700029396.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300966"],"gpt_icon":0},{"id":"2577884153","title":"共同药业连亏1年半 2021上市中信证券保荐两募资共6亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2577884153","media":"中金财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577884153?lang=zh_cn&edition=full","pubTime":"2025-10-21 15:17","pubTimestamp":1761031026,"startTime":"0","endTime":"0","summary":"中国经济网北京10月21日讯 共同药业 2025年半年度报告显示，2025年上半年，公司实现营业收入3.02亿元，同比增长29.33%；归属于上市公司股东的净利润-1115.25万元，上年同期为-511.86万元；归属于上市公司股东的扣除非经常性损益的净利润-1021.91万元，上年同期为-492.68万元；经营活动产生的现金流量净额为-579.29万元，上年同期为3411.45万元。　　共同药业本次发行募集资金总额23,896.00万元；扣除发行费用后，募集资金净额为19,418.21万元。","market":"sh","thumbnail":" http://caiji.3g.cnfol.com/colect/202510/21/20251021441639.jpg","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202510/21/20251021441639.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20251021/31723491.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["LU1328615791.USD","06030","BK0239","LU0405327148.USD","BK1521","LU1064130708.USD","LU1794554557.SGD","LU2495084118.USD","BK1516","LU1655091616.SGD","BK0183","300966","BK1564","BK0028","LU1064131003.USD","BK1147","LU1997245094.SGD","BK0276","600030","LU1255011170.USD","LU1997244956.HKD","BK0188","LU2289578879.USD","BK0196","LU1997245177.USD","LU0405327494.USD","LU2148510915.USD","LU1720050803.USD","BK0012"],"gpt_icon":0},{"id":"2575438337","title":"共同药业：10月15日接受机构调研，国信证券、知远投资管理有限公司等多家机构参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2575438337","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2575438337?lang=zh_cn&edition=full","pubTime":"2025-10-16 19:31","pubTimestamp":1760614273,"startTime":"0","endTime":"0","summary":"证券之星消息，2025年10月16日共同药业发布公告称公司于2025年10月15日接受机构调研，国信证券、知远投资管理有限公司、深圳前海金色阳光资产管理有限公司、耕霁(上海)投资管理有限公司、上海朗程投资管理有限公司、上海协能科技有限公司、浙江惟像企业管理有限公司、浙江丰道投资管理有限公司、国泰海通证券、财达证券、华福证券、中信建投、峰境基金、德创基金、源达信息证券研究所、北京天襄资本管理有限公司参与。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101600032309.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0188","002736","BK0028","300966","BK0183","BK0276"],"gpt_icon":0},{"id":"2574132067","title":"共同药业2025年第三季度可转债转股453张","url":"https://stock-news.laohu8.com/highlight/detail?id=2574132067","media":"中金财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2574132067?lang=zh_cn&edition=full","pubTime":"2025-10-09 17:09","pubTimestamp":1760000995,"startTime":"0","endTime":"0","summary":"中访网数据 湖北共同药业股份有限公司发布2025年第三季度可转换公司债券转股情况公告。报告期内，“共同转债”共有453张完成转股，对应票面金额45,300元，合计转换为公司股票1,661股。截至2025年9月30日，公司剩余可转债数量为3,798,888张，剩余票面总金额为379,888,800元。本次转股完成后，公司总股本由115,279,416股增加至115,281,077股。根据公告，“共同转债”的转股期限为2023年6月2日至2028年11月27日，当前转股价格为27.12元/股。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20251009/31692816.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0239","300966"],"gpt_icon":0},{"id":"2513265468","title":"共同药业(300966.SZ)拟斥2000万元至3000万元实施回购","url":"https://stock-news.laohu8.com/highlight/detail?id=2513265468","media":"智通财经","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513265468?lang=zh_cn&edition=full","pubTime":"2025-02-21 19:11","pubTimestamp":1740136301,"startTime":"0","endTime":"0","summary":"智通财经APP讯，共同药业(300966.SZ)公告，公司拟使用自有资金及浦发银行提供的股票回购专项贷款资金实施回购公司股份方案。回购资金总额不低于人民币2000万元(含)，不超过人民币3000万元(含);价格不超过人民币23.84元/股。回购期限自董事会审议通过回购股份方案之日起12个月内。目前公司已取得浦发银行出具的《贷款承诺函》，承诺为公司回购A股股份提供专项贷款支持，借款金额最高不超过人民币2700万元(含)，借款期限为3年。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1252903.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","300966"],"gpt_icon":0},{"id":"2513268780","title":"共同药业最新公告：拟以2000万元至3000万元回购股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2513268780","media":"证券之星","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513268780?lang=zh_cn&edition=full","pubTime":"2025-02-21 18:30","pubTimestamp":1740133831,"startTime":"0","endTime":"0","summary":"共同药业公告称，公司计划使用自有资金及金融机构提供的股票回购专项贷款资金，以集中竞价方式回购公司股份，回购价格不超过23.84元/股，资金总额不低于2,000万元（含），不超过3,000万元（含）。回购的股份将用于股权激励或员工持股计划，若未能在回购完成后三年内使用完毕，将依法注销。公司已取得浦发银行出具的《贷款承诺函》，承诺为公司回购A股股份提供最高不超过2,700万元（含）的专项贷款支持。以上内容为证券之星据公开信息整理，由智能算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025022100034783.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300966"],"gpt_icon":0},{"id":"2509772654","title":"【企业动态】共同药业新增1件法院诉讼，案由为与公司有关的纠纷案件执行","url":"https://stock-news.laohu8.com/highlight/detail?id=2509772654","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509772654?lang=zh_cn&edition=full","pubTime":"2025-02-08 05:58","pubTimestamp":1738965493,"startTime":"0","endTime":"0","summary":"证券之星消息，根据企查查数据显示，2月7日共同药业（300966）新增1件法院诉讼如下：案号：（2025）鄂0111执1026号法院：武汉市洪山区人民法院案由：与公司有关的纠纷案件执行申请人：苏某某被执行人：湖北共同药业股份有限公司案件类型：执行立案日期：2025年2月7日数据来源：企查查以上内容为证券之星据公开信息整理，由智能算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025020800054060.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300966"],"gpt_icon":0},{"id":"2509095104","title":"2月5日共同药业发布公告，股东减持39.47万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2509095104","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509095104?lang=zh_cn&edition=full","pubTime":"2025-02-05 19:01","pubTimestamp":1738753278,"startTime":"0","endTime":"0","summary":"证券之星消息，2月5日共同药业发布公告《共同药业:关于控股股东、实际控制人的一致行动人减持计划期限届满暨减持结果的公告》，其股东丹江口市共同创新投资合伙企业(有限合伙)于2024年10月28日至2025年1月27日间合计减持39.47万股，占公司目前总股本的0.3424%，变动期间该股股价下跌21.51%，截止1月27日收盘报15.4元。股东增减持详情见下表：根据共同药业2024年三季报公布的十大股东详情如下：以上内容为证券之星据公开信息整理，由智能算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025020500029199.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300966"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1773869077259,"stockEarnings":[{"period":"1week","weight":-0.0023},{"period":"1month","weight":-0.0033},{"period":"3month","weight":0.0704},{"period":"6month","weight":-0.0111},{"period":"1year","weight":0.1899},{"period":"ytd","weight":0.0818}],"compareEarnings":[{"period":"1week","weight":-0.017},{"period":"1month","weight":-0.0047},{"period":"3month","weight":0.0481},{"period":"6month","weight":0.0636},{"period":"1year","weight":0.1846},{"period":"ytd","weight":0.0237}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"湖北共同药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"14193人(较上一季度增加13.13%)","perCapita":"5380股","listingDate":"2021-04-09","address":"湖北省襄阳市宜城市小河镇高坑一组","registeredCapital":"11528万元","survey":"　　湖北共同药业股份有限公司的主营业务是甾体药物原料的研发、生产及销售。公司的主要产品是4-雄烯二酮（4-AD）、雄二烯二酮（ADD）、双降醇（BA）、9-羟基雄烯二酮（9-OH-AD）。","listedPrice":8.24},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"共同药业(300966)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供共同药业(300966)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"共同药业,300966,共同药业股票,共同药业股票老虎,共同药业股票老虎国际,共同药业行情,共同药业股票行情,共同药业股价,共同药业股市,共同药业股票价格,共同药业股票交易,共同药业股票购买,共同药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"共同药业(300966)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供共同药业(300966)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}